Jim Cramer’s Charitable Trust plans to cut two health care positions after sharp gains, locking in part of its returns while retaining both stocks as a counterweight to data-center exposure, CNBC reported.
The CNBC report, published Thursday, Nov. 5, described sales planned for that session: 50 shares of Cardinal Health at about $273 apiece and 10 Eli Lilly shares at roughly $1,420 each. The trades were presented as plans, not completed transactions.
If carried out, the Cardinal Health sale would leave the Trust with 375 shares and reduce the stake’s portfolio weight to 2.75% from 3%. CNBC said the shares targeted for sale were acquired in March 2026, putting the expected gain on that portion at 20%.
The Eli Lilly order would leave 70 shares in the portfolio and lower the position’s weight to 2.6% from 3%. The Trust expects a 500% gain on shares it bought in February 2022, CNBC reported.
Both stocks had advanced by more than 20% since September ended, CNBC said. Cardinal Health’s latest quarterly results topped forecasts, and the company raised its full-year outlook Thursday. The stock rose more than 4% and ranked among the S&P 500’s stronger performers during an otherwise weak session. Eli Lilly traded modestly higher after raising its outlook following the previous week’s results, according to CNBC.
The portfolio weights show each stock’s share of the Trust’s holdings, rather than returns on the shares. The Trust’s stated reason for continuing to own the health care companies is to diversify from its data-center exposure. CNBC described health care as holding up better Thursday as technology and data-center shares fell sharply.
CNBC framed the transactions as profit-taking after the recent advance.
